Insmed - INSM Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 12 month price targets for Insmed's stock. Their INSM share price forecasts range from $28.00 to $53.00. On average, they predict the company's stock price to reach $43.36 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price.
View analysts price targets for INSM or view top-rated stocks among Wall Street analysts.

Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM shares have increased by 8.2% and is now trading at $21.62.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our INSM earnings forecast.

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.13. The biopharmaceutical company earned $46.80 million during the quarter, compared to the consensus estimate of $49.23 million. Insmed had a negative net margin of 179.37% and a negative trailing twelve-month return on equity of 319.03%. The firm's revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.63) EPS.

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.77%), Peregrine Capital Management LLC (0.26%), Scout Investments Inc. (0.24%), Rice Hall James & Associates LLC (0.18%), Hennion & Walsh Asset Management Inc. (0.10%) and State of New Jersey Common Pension Fund D (0.09%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends.

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INSM stock can currently be purchased for approximately $21.62.

Insmed (NASDAQ:INSM) has a market capitalization of $2.93 billion and generates $188.46 million in revenue each year. The biopharmaceutical company earns $-434,650,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis.

The company employs 373 workers across the globe.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.